Drug development process would be hampered by "Access to Medical Treatments Act," FDA testifies.
FDA AUTHORITY TO REMOVE PRODUCTS FROM MARKET WOULD BE COMPROMISED by "The Access to Medical Treatment Act" (S 1035), FDA Executive Assistant to the Commissioner Jerold Mande asserted at a July 30 hearing on the bill before the Senate Labor & Human Resources Committee. The bill, sponsored by Minority Leader Daschle (D-S.D.), would allow health practitioners to administer unapproved drugs, devices, foods or dietary supplements as long as there is no evidence the treatment causes harm and the patient is informed about the treatment and its possible side effects.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth